Health ❯ Healthcare ❯ Clinical Research

Phase 1 Trials

Patient Outcomes Dose Escalation Studies Nimacimab Efficacy Studies INLIGHT Trial Safety and Efficacy Phase 2 Trials

Lilly’s One‑Dose Gene Editor Cuts LDL Cholesterol by Up to 62% in Early Trial

Dose-related PCSK9 and LDL-C reductions came with an early favorable safety readout and leave Lilly poised to begin Phase 2 by year-end.

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial